Navigation Links
MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Date:1/4/2011

MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 8:00 a.m. PT in San Francisco.

A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com. A replay will also be available within 24 hours for seven days following the presentation.

About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX™ orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com. CONTACT: Alex BowieWCG(212) 301-7201abowie@wcgworld.com
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  While nearly three-quarters of ... can have on their health, only about half report ... to the results of a new survey announced today ... the start of National Osteoporosis Month, Hologic is raising ... affects nearly 56 million Americans. Osteoporosis is ...
(Date:4/29/2016)... April 29, 2016 ReportsnReports.com ... 2016" market research report that provides an overview ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:4/29/2016)... , April 29, 2016 ... life science laboratory due to the growing demands for ... advance technology, contemporary automated systems are already adept of ... by slow, tedious and manual labor. Instrumentation continues to ... not even conceivable just a few years ago. Originally ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... ... – a web application that helps people assess their risk of developing Alzheimer’s ... app will provide users a “Risk Reduction Score™” that summarizes how their lifestyle ...
(Date:5/3/2016)... Baltimore, Md. (PRWEB) , ... May 03, 2016 , ... ... devastating consequences of inappropriate or excessive levels of alcohol use. Alcohol and its ... fetal alcohol spectrum disorders to the susceptibility to strokes in those 65 years and ...
(Date:5/3/2016)... ... May 03, 2016 , ... SELEX (systematic evolution of ... a random library of sequences depending on their attraction for a target molecule. ... selection is commonly performed using filters, panning, or affinity chromatography separations. However, these ...
(Date:5/3/2016)... Chicago (PRWEB) , ... May 03, 2016 , ... ... has hired award-winning creative director Joe Ferrazano to serve in the newly created ... Ferrazano will be overseeing the agency’s creative efforts in the Chicago and LA ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Elizabeth Murray ... pet parrots to join her with one on her shoulder and one on her ... a parking lot because of years of mitral valve prolapse. , The valves of ...
Breaking Medicine News(10 mins):